Emcure (EMCURE) Q1 FY27 Profit Jumps 36% as Exports Drive Growth
The pharma company's Q1 profit growth significantly outpaced revenue, powered by a surging international business and improved operating leverage.
Emcure Pharmaceuticals started FY27 with strong momentum. Profit grew 36% year-on-year, far ahead of a 23% revenue rise, as international sales became the dominant growth engine and margins expanded.
Emcure Pharmaceuticals entered the second year of its five-year plan needing to show its domestic business was back on track and that international growth could keep delivering. The first quarter answered both, with profit growth racing ahead of a strong top line. Profit after tax surged 36.2% year-on-year to ₹292.5 crore, while revenue rose 22.8% to ₹2,580.5 crore.
The numbers show a company accelerating. Sequentially, profit grew 20% from the March quarter, and the net profit margin improved to 11.3%, up 110 basis points from a year ago.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin
| Metric | CurrentQ1 FY27 | PreviousQ4 FY26 | Same quarter LYQ1 FY26 |
|---|---|---|---|
| Revenue (₹ Cr) | 2,580.45YoY +23% | 2,469.70 | 2,100.54 |
| Profit (₹ Cr) | 292.49YoY +36% | 243.74 | 214.79 |
| Net Profit Margin | 11.3%YoY +11% | 9.9% | 10.2% |
The Export Engine Takes Over
The story is one of geography. International sales jumped 34.2% and now make up 58% of total revenue, according to the company's earnings call. Europe grew 33%, Canada 25%, and the Rest of the World segment—driven by anti-retroviral (ARV) drugs—surged 45%. Management told Investing.com that about 12% of this international growth came from favourable currency movements.
This mix shift comes with a cost: it pushed the gross margin down 340 basis points to 58.4%. But the company more than offset this through what CEO Satish Mehta called “productivity gains and operating leverage.” The result was a 50-basis-point expansion in EBITDA margin to 19.7%, which flowed through to the bottom line.
A Domestic Business in Recovery
At home, the picture is one of repair turning to acceleration. Domestic revenue grew 10.2%, a return to double-digits after the disruption from integrating Zuventus Healthcare. Management indicated on the QuarterMark call that organic growth, excluding in-licensed products, was a softer 6-7%.
However, signs point to improvement. A Motilal Oswal report noted domestic sales growth accelerated in August and September, outperforming the market. The focus now is on execution from the restructured Zuventus team and scaling up new partnerships, like the co-marketing deal for semaglutide (Poviztra) with Novo Nordisk.
Guidance and the Path Ahead
Management has upgraded its confidence, now expecting revenue growth at the higher end of its low-to-mid-teens guidance for FY27. The outlook, however, carries a revised trade-off. The faster international mix means the full-year gross margin is now seen around 59%, down from earlier expectations of 60-61%.
The company is betting that operating leverage will continue to drive profitability. It targets a 70-100 basis point expansion in EBITDA margin for the year. Capital expenditure is planned at ₹400-425 crore, and R&D spending is set to rise to 4-5% of revenue to feed the pipeline.
Key Points
- International business was the primary growth driver, surging 34% and contributing 58% of total revenue.
- Net profit margin expanded 110 basis points to 11.3% as operating leverage offset gross margin pressure from the sales mix.
- Domestic growth recovered to 10%, with management expecting further acceleration in the second half of FY27.
- Full-year revenue guidance is now at the higher end of low-to-mid teens, though gross margin expectations have been tempered to around 59%.
- The company received a Voluntary Action Indicated (VAI) classification from the USFDA for its Sanand facility, closing the inspection without major issues.
Hexa Perspective
Emcure’s quarter confirms a strategic pivot: it is increasingly an export-led story. The margin expansion demonstrates an ability to manage the profitability trade-off that comes with this faster-growing, but lower-margin, international mix. The test for the coming quarters is whether the domestic recovery can gain enough steam to provide a balanced growth profile, or if the company’s earnings will become disproportionately reliant on international execution and currency trends. The raised guidance suggests management sees the momentum holding, but investors will watch for the delivery of promised operating leverage against the backdrop of rising R&D spend and a temporarily higher debt load from recent acquisitions.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.